ZC3HAV1 and cancer: In consideration of the heterogeneity of MXRA8 and ZAP expression in cancers, we highlight the importance of using MXRA8 and ZAP as a potential dual-biomarker for predicting curative effects and selecting patients for OVM on multiple solid tumor types in clinical use.